journal article·2026-06Open access

NUP85 Mediates Endoplasmic Reticulum Stress through the USP47/ASK1 Signaling Pathway to Regulate the Progression of Liver Fibrosis

Dashuai Yang, Haoran Yang, Linxin Pan, Chang Tian, Fucheng Zuo, Shilei Huang, Xianrui Li, Ming Chen, Cheng Qian, Jie Wang, Zhaolin Chen, Tao Xu

Advanced Science· Volume 13· Issue 33

Abstract

ABSTRACT Liver fibrosis is a pathological process caused by excessive deposition of extracellular matrix (ECM) in the liver stimulated by chronic injury or inflammation. Nuclear pore protein 85 (NUP85) has been implicated in the development of various liver diseases. However, its involvement in liver fibrosis remains unclear. The present study aimed to explore the role of NUP85 in liver fibrosis. The expression level of NUP85 was found to be elevated in the liver tissues of liver fibrosis patients and mice. Knockdown of NUP85 not only ameliorated liver injury and collagen deposition, but also suppressed endoplasmic reticulum stress (ERS). Conversely, the opposite pathological and biochemical changes are observed with NUP85 overexpression. Mechanistically, NUP85 competitively binds ubiquitin‐specific peptidase 47 (USP47) to apoptosis signal‐regulating kinase 1 (ASK1), deubiquitinates lysine residue 805 of ASK1, and regulates the activation of ASK1, thereby exacerbating collagen deposition and ERS. Furthermore, we developed a CREKA‐coupled liposome as a targeted delivery system to deliver Mogroside V (MV), a pharmacological inhibitor of NUP85, to activated HSCs and attenuate liver fibrosis. Taken together, the present study demonstrated that NUP85 is a novel regulator of liver fibrosis and that the NUP85‐USP47‐ASK1 signaling pathway might be a strategy for therapeutic intervention.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Endoplasmic Reticulum Stress and Disease · Liver physiology and pathology · Liver Disease Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province School of Pharmacy Anhui Medical University Hefei China

Anhui Institute of Medicine Hefei China

School of Life Science Anhui Medical University Hefei China

Center for Scientific Research Auhui Medical University Hefei China

Department of Emergency Surgery The Second Affiliated Hospital of Anhui Medical University Hefei China

Department of Pharmacy The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China

Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy Hefei Anhui China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Anhui Province · Science Fund for Distinguished Young Scholars of Anhui Province

References (46)

Show source-provided references
1. 10.1002/advs.20250422310.1002/advs.202504223 ↗
2. 10.1136/egastro-2023-10004010.1136/egastro-2023-100040 ↗
3. 10.1016/j.metabol.2024.15580010.1016/j.metabol.2024.155800 ↗
4. 10.1002/advs.20230689910.1002/advs.202306899 ↗
5. 10.1136/egastro-2024-10011510.1136/egastro-2024-100115 ↗
6. 10.3350/cmh.2024.035110.3350/cmh.2024.0351 ↗
7. 10.1016/j.jhep.2022.12.03410.1016/j.jhep.2022.12.034 ↗
8. 10.1016/j.bioactmat.2024.05.03410.1016/j.bioactmat.2024.05.034 ↗
9. 10.1016/j.jhep.2023.05.04310.1016/j.jhep.2023.05.043 ↗
10. 10.1186/s12951‐025‐03900‐2.Z10.1186/s12951‐025‐03900‐2.Z ↗
11. 10.7150/ijbs.9233710.7150/ijbs.92337 ↗
12. 10.1111/liv.1554710.1111/liv.15547 ↗
13. Analysis of Correlation Between High Expression of Nucleoporin 85 (NUP85) and Immune Cell Infiltration in Hepatocellular Carcinoma
14. 10.1038/s41467‐024‐46135‐910.1038/s41467‐024‐46135‐9 ↗
15. 10.1002/adma.20231044310.1002/adma.202310443 ↗
16. 10.34133/research.025610.34133/research.0256 ↗
17. 10.1002/hep.3082210.1002/hep.30822 ↗
18. 10.1016/j.chmed.2023.07.00310.1016/j.chmed.2023.07.003 ↗
19. 10.1016/j.chmed.2024.12.00310.1016/j.chmed.2024.12.003 ↗
20. 10.1002/advs.20240502610.1002/advs.202405026 ↗
21. 10.1038/s41418‐023‐01130‐310.1038/s41418‐023‐01130‐3 ↗
22. 10.1016/j.apsb.2022.03.01410.1016/j.apsb.2022.03.014 ↗
23. 10.1016/j.cmet.2024.04.00310.1016/j.cmet.2024.04.003 ↗
24. 10.1002/advs.20240567810.1002/advs.202405678 ↗
25. 10.1016/j.jhep.2019.09.03310.1016/j.jhep.2019.09.033 ↗
26. 10.7150/ijbs.8353010.7150/ijbs.83530 ↗
27. 10.1002/hep.2295210.1002/hep.22952 ↗
28. 10.1038/s41467‐024‐55745‐210.1038/s41467‐024‐55745‐2 ↗
29. 10.7150/thno.8970310.7150/thno.89703 ↗
30. 10.1007/s10495‐019‐01568‐210.1007/s10495‐019‐01568‐2 ↗
31. 10.1053/j.gastro.2015.09.03910.1053/j.gastro.2015.09.039 ↗
32. 10.1038/cddis.2011.5210.1038/cddis.2011.52 ↗
33. 10.1016/j.freeradbiomed.2024.12.05510.1016/j.freeradbiomed.2024.12.055 ↗
34. 10.1038/s41392‐022‐01299‐y10.1038/s41392‐022‐01299‐y ↗
35. 10.1038/s41467‐023‐41145‐510.1038/s41467‐023‐41145‐5 ↗
36. 10.3350/cmh.2022.032710.3350/cmh.2022.0327 ↗
37. 10.1016/j.phymed.2022.15396010.1016/j.phymed.2022.153960 ↗
38. 10.1089/1523086026019621810.1089/15230860260196218 ↗
39. 10.1021/acs.jafc.3c0810810.1021/acs.jafc.3c08108 ↗
40. 10.1016/j.freeradbiomed.2017.07.02010.1016/j.freeradbiomed.2017.07.020 ↗
41. 10.1093/cvr/cvae21710.1093/cvr/cvae217 ↗
42. 10.1002/hep.3053710.1002/hep.30537 ↗
43. 10.1038/nm.445310.1038/nm.4453 ↗
44. 10.1136/gutjnl‐2023‐33144710.1136/gutjnl‐2023‐331447 ↗
45. 10.1016/j.biomaterials.2023.12204910.1016/j.biomaterials.2023.122049 ↗
46. 10.1002/advs.20240408910.1002/advs.202404089 ↗